Delavirdine is expected to raise the levels of atorvastatin,
simvastatin and
lovastatin. This expectation is supported by a case of rhabdomyolysis, which developed in a patient taking atorvastatin and
delavirdine.
One of the manufacturers of
simvastatin contraindicates delavirdine, and the US manufacturer of
delavirdine advises against the use of either
simvastatin or
lovastatin. Patients should be made aware of the risks of myopathy and rhabdomyolysis, and asked to promptly report muscle pain, tenderness or weakness, especially if accompanied by
malaise, fever or dark urine.